CLDN6 Research Reagents

CLDN6 is located on chromosome 16p3.3 and has a molecular weight of about 20-40 kDa. The claudins have similar structures to each other, having four transmembrane structural domains, two extracellular loops, and two intracellular tail regions. CLDN6 possesses a C-terminal PDZ binding site allows tight junction proteins to interact with certain intracellular proteins, which is essential in cell junctions and epithelial tissue permeability

More and more studies have shown that abnormal expression of CLDN6 can participate in the occurrence and development of breast cancer, ovarian cancer, cervical cancer, gastric cancer, lung cancer, and other malignant tumors. CLDN6, as an important molecule in the formation of the cytoskeleton and the regulation of cell signaling pathways, can affect the growth process of cells, which provides a new direction for the diagnosis and intervention of tumors. At present, a variety of drugs targeting CLDN6 are in the clinical and preclinical stages and are used for the treatment of many tumors.

More Interesting read related CLDN6：CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2!

Popular Product

Recombinant Human Claudin-6(CLDN6)-VLPs (Active) (CSB-MP005508HU(A4))

Validated Data

High Specifity Validated by Western Blot

The specifity was validated by western blot. CSB-MP005508HU(A4) is detected by Mouse anti-6*His monoclonal antibody.

Excellent Bioactivity Validated by Functional ELISA

Immobilized Human CLDN6 at 10 μg/ml can bind Anti-CLDN6/9 recombinant antibody (CSB-RA005508MA1HU), the EC₅₀ is 1.501-2.035 ng/mL

TEM

The presence of VLP-like structures was confirmed by TEM